Avenue Therapeutics, Inc.
1111 Kane Concourse
Suite 301
Bay Harbor Islands, FL 33154
United States
781 652 4500
https://www.avenuetx.com
版塊: Healthcare
行業: Biotechnology
全職員工: 3
高階主管
| 名稱 | 頭銜 | 支付 | 行使價 | 出生年份 |
|---|---|---|---|---|
| Dr. Alexandra MacLean M.D. | CEO & Director | 386.35k | 無 | 1968 |
| Mr. David Jin | Interim CFO, COO & Corporate Secretary | 無 | 無 | 1991 |
| Dr. Lindsay Allan Rosenwald | Executive Director | 無 | 無 | 1955 |
| Dr. Xiaoqin Lu M.D. | Consultant | 978.81k | 無 | 1975 |
| Dr. Scott A. Reines M.D., Ph.D. | Interim Chief Medical Officer | 64.63k | 無 | 1947 |
| Mr. Srinivas Subramanian | Executive Vice President | 無 | 無 | 1971 |
截止 2023年12月31日為止計算的金額，現金賠償則計算至上一個財政年度末止。薪資是指薪俸、獎金等。已行使價是指財政年度期間已行使的期權價值。貨幣為 EUR。
描述
Avenue Therapeutics, Inc., a specialty pharmaceutical company, focuses on the development and commercialization of therapies for the treatment of neurologic diseases. Its product candidates include AJ201, which is in a Phase 1b/2a clinical trial for the treatment of spinal and bulbar muscular atrophy; intravenous tramadol for the treatment of post-operative acute pain; and BAER-101 for the treatment of epilepsy and panic disorders. The company was incorporated in 2015 and is based in Bay Harbor Islands, Florida.
公司管治
截至 無 止，Avenue Therapeutics, Inc. 的 ISS 管治質素評分為 無。 Pillar 分數正在審核中：無；董事會：無；股東權利：無；現金賠償：無。
企業管治評分的資料提供： Institutional Shareholder Services (ISS). 評分將以 1 至 10 分顯示 (與指數或地區相關)。1 分表示較低的管治風險，而 10 分表示較高的管治風險。
